Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference
Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference


Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving

Axcella to Present at J.P. Morgan Healthcare Conference
Axcella to Present at J.P. Morgan Healthcare Conference


Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving

Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones


Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein

Stoke Therapeutics Added to NASDAQ Biotechnology Index
Stoke Therapeutics Added to NASDAQ Biotechnology Index


Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Axcella Presents Data at ASH Annual Meeting
Axcella Presents Data at ASH Annual Meeting


Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health

Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Axcella Strengthens Executive Team with Key Addition and Promotion
Axcella Strengthens Executive Team with Key Addition and Promotion


Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today

Axcella Announces Issuance of Broad Patent Covering EMM Compositions
Axcella Announces Issuance of Broad Patent Covering EMM Compositions


Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today

Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update
Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update


Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health

Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010
Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010


Axcella Health Inc. (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health

Axcella Presents Data at The Liver Meeting™ Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates
Axcella Presents Data at The Liver Meeting™ Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates


Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel interventions to address dysregulated metabolism and support health, today announced that it

Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics to Present at Upcoming Investor Conferences in November


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Why Shares of EV Stocks Nio, Li Auto, and XPeng Are Driving Higher This Week: https://g.foolcdn.com/editorial/images/775496/charging-an-electric-vehicle.jpg
Why Shares of EV Stocks Nio, Li Auto, and XPeng Are Driving Higher This Week

Extending the rises they all enjoyed in the last full week of April, shares of electric vehicle (EV) makers Nio (NYSE: NIO), XPeng (NYSE: XPEV), and Li Auto (NASDAQ: LI) have all continued motoring

3 Dow Stocks That Are No-Brainer Buys in May: https://g.foolcdn.com/editorial/images/775439/nyse-wall-street-trading-new-york-financial-stock-market-getty.jpg
3 Dow Stocks That Are No-Brainer Buys in May

For nearly 128 years, the iconic Dow Jones Industrial Average (DJINDICES: ^DJI) has served as one of the premier barometers of Wall Street's health. Since its official debut on May 26, 1896, it's

3 Top ETFs to Buy for Passive Income in May: https://g.foolcdn.com/editorial/images/774925/a-pad-with-passive-income-written-on-it.jpg
3 Top ETFs to Buy for Passive Income in May

Investing in exchange-traded funds (ETFs) can be a great way to generate passive income. Many ETFs focus on holding income-generating assets like dividend-paying stocks or bonds. Meanwhile, you

3 No-Brainer Stocks to Buy With $200 Right Now: https://g.foolcdn.com/editorial/images/774971/two-hundred-dollars-cash-money-invest-retire-stocks-getty.jpg
3 No-Brainer Stocks to Buy With $200 Right Now

Investors have been taken for quite the ride over the previous four years. All three of Wall Street's major stocks indexes – the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite -- have

3 Dates for Disney Stock Investors to Circle in May: https://g.foolcdn.com/editorial/images/774968/emma_bunton_wdw_58_ot.jpg
3 Dates for Disney Stock Investors to Circle in May

A third of the way into 2024, Walt Disney (NYSE: DIS) is the second-biggest gainer among the 30 components of the Dow Jones Industrial Average. The stock's 25% jump this year is notable, especially

2 Dow Jones Dividend Stocks That Still Look Like Bargains: https://g.foolcdn.com/editorial/images/774700/individual-investors-at-home-getty.jpg
2 Dow Jones Dividend Stocks That Still Look Like Bargains

It's already been a pretty good year for two of America's three main market indexes. Enthusiasm for growth stocks already pushed the Nasdaq Composite and S&P 500 indexes more than 6% higher since

5 of the "Magnificent Seven" Stocks Pay a Dividend. In Mere Hours, a New Member May Join the Club: https://g.foolcdn.com/editorial/images/774734/getting-paid-dividends-getty.jpg
5 of the "Magnificent Seven" Stocks Pay a Dividend. In Mere Hours, a New Member May Join the Club

Following a volatile start to the decade, the bulls are, once again, running wild on Wall Street. Despite a modest pullback, investors have witnessed the ageless Dow Jones Industrial Average

Are Stocks Going to Crash if Joe Biden Wins and Democrats Control Congress? Here's What History Says About Stock Market Returns When Democrats Win.: https://g.foolcdn.com/editorial/images/774270/joe-biden-address-reporters-wh-photo-by-adam-schultz.jpg
Are Stocks Going to Crash if Joe Biden Wins and Democrats Control Congress? Here's What History Says About Stock Market Returns When Democrats Win.

In just a little over six months, Americans from across the nation will head to the polls or mail in their ballots to determine who'll lead our great country for the next four years.

While there are

1 Little-Known Vanguard Index Fund to Buy Before It Soars 50%, According to a Wall Street Analyst: https://g.foolcdn.com/editorial/images/774703/strategy-3.jpg
1 Little-Known Vanguard Index Fund to Buy Before It Soars 50%, According to a Wall Street Analyst

Many investors are familiar with the three major U.S. stock market indexes. I am talking about the S&P 500 (SNPINDEX: ^GSPC), the Dow Jones Industrial Average (DJINDICES: ^DJI), and the Nasdaq